Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Organon & Co.

OGNNYSEPharmaceuticalsWILMINGTON, US-DE, USMid capWebsite ↗
  • Russell 1000

What Organon & Co. is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $6.13 billion, down 2.4% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.57 billion, down 14% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.17 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
  • Long-term debt issued in the fiscal year to December 31, 2025: $1.06 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (April 30, 2026): sentiment -0.30 on a −1 to +1 scale (negative), confidence 0.20 of 1.Palanor Discourse
  • Latest annual report (filed February 24, 2026): 9 risk factors added, 6 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $0.2 million on the open market.SEC Form 4
  • 631 institutional managers reported a position at June 30, 2026 (+22 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 2 (1 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Organon & Co. yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Organon & Co.: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$0.6BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: revenue, trailing twelve months

$ billions, from SEC filings

$6.1BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Organon & Co.: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: debt maturity schedule, latest annual report

Scheduled repayments of long-term debt principal by year from the fiscal year end, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

2.1Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Organon & Co.: guidance raised minus lowered

Guidance Ledger statements by quarter

−2.0Data to Dec 2025
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Organon & Co.: earnings call sentiment

Palanor Discourse score per call, −1 to +1

−0.30Data to Apr 2026
ImageDataPalanor calculation
Business

Organon & Co.: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.20Data to Apr 2026
ImageDataPalanor calculation
Business

Organon & Co.: risk factors added per annual report

New Item 1A risk factors in each 10-K

9.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Organon & Co.: H-1B filings certified

Labor Condition Applications by quarter received

2.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Organon & Co.: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$0.20MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Organon & Co.: institutional holders

Managers reporting a position on Form 13F, by quarter

631.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Lobbying
    Lobbying report (ORGANON & CO.)third_quarter 2026 · $0.3 million
  3. Oct 18, 2026Lobbying
    Lobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
  4. Oct 18, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL AND ASSOCIATES)third_quarter 2026 · $0.0 million
  5. Jul 23, 20268-K
    Shareholder vote resultsItem 5.07
  6. Jul 20, 2026Lobbying
    Lobbying report (WILLIAMS AND JENSEN, PLLC)second_quarter 2026 · $0.1 million
  7. Jul 20, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)second_quarter 2026 · $0.0 million
  8. Jul 20, 2026Lobbying
    Lobbying report (ORGANON & CO.)second_quarter 2026 · $0.3 million
  9. Jul 18, 2026Lobbying
    Lobbying report (TIBER CREEK GROUP)second_quarter 2026 · $0.1 million
  10. Jun 11, 20268-K
    Director or officer changeItem 5.02
  11. Jun 11, 20268-K
    Shareholder vote resultsItem 5.07
  12. Apr 27, 20268-K
    Material agreement signedItem 1.01
  13. Apr 27, 20268-K
    Director or officer changeItem 5.02
  14. Mar 10, 2026Patent
    Patent granted: USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITISUS 12569453
  15. Feb 24, 202610-K
    Annual report (10-K)9 risk factors added, 6 removed
  16. Nov 7, 20258-K
    Director or officer changeItem 5.02
  17. Nov 4, 2025Patent
    Patent granted: POSTPARTUM UTERINE HEMORRHAGE DEVICEUS 12458399
  18. Oct 30, 20258-K
    Director or officer changeItem 5.02
  19. Oct 27, 20258-K
    Director or officer changeItem 5.02
  20. Jun 12, 20258-K
    Director or officer changeItem 5.02
  21. Jun 12, 20258-K
    Shareholder vote resultsItem 5.07
  22. May 20, 2025Patent
    Patent granted: UTERINE HEMORRHAGE CONTROLLING SYSTEM AND METHODUS 12303168
  23. May 6, 2025Patent
    Patent granted: UTERINE HEMORRHAGE CONTROLLING SYSTEM AND METHODUS 12290285
  24. Apr 15, 20258-K
    Director or officer changeItem 5.02
  25. Apr 15, 2025Patent
    Patent granted: PROCESS FOR PREPARING TAPINAROFUS 12275696
  26. Feb 28, 202510-K
    Annual report (10-K)4 risk factors added, 6 removed
  27. Jan 21, 20258-K
    Director or officer changeItem 5.02
  28. Dec 6, 20248-K
    Director or officer changeItem 5.02
  29. Feb 26, 202410-K
    Annual report (10-K)4 risk factors added, 4 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Jazz Pharmaceuticals JAZZ$4.6B$1.6BJun 30, 2026
Zoetis ZTS$9.5B$2.3BJun 30, 2026
Viatris VTRS$14.7B$1.9BJun 30, 2026
Corcept Therapeutics CORT$0.8B$0.1BJun 30, 2026
Bristol Myers Squibb BMY$49.2B$11.4BJun 30, 2026
Encompass Health EHC$6.2B$0.4BJun 30, 2026
Steris STE$6.0B$0.9BJun 30, 2026
Edwards Lifesciences EW$6.5B$1.4BJun 30, 2026

Identity

SEC CIK
1821825
LEI
549300AMCKY57OK2CO56
Wikidata
Q903372

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.